A multicenter, randomized, global phase 3 study to assess the efficacy and safety of intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as monotherapy compared with standard of care systemic chemotherapy in adults with locally recurrent, inoperable, or metastatic soft tissue sarcomas (STS; INVINCIBLE-3).
Bibliographic record
Abstract
TPS11588 Background: Soft tissue sarcomas (STS) are a rare and diverse set of tumors. Systemic chemotherapy provides limited benefit for metastatic disease. INT230-6 is a novel formulation of cisplatin (CIS) and vinblastine (VIN) with a tissue dispersion enhancer (SHAO). The drug’s unique chemistry permits dispersion throughout tumors and diffusion into the cancer cells after IT injections. The drug causes apoptosis and recruits T-cells to the tumor. An open-label, phase 1/2 study was completed with locally advanced, unresectable, or metastatic adult patients with 11 STS subtypes. Patients had a median of 3 prior lines. Biopsied tissue from pre- and post-dosed tumors 2 showed immune engagement post-dose. PK data showed that >95% of VIN stayed in the tumor. There were no dose-limiting toxicities up to 175 mL (87.5 mg CIS, 17.5 mg VIN). The disease control rate was 93%. Uninjected tumors shrank. The median OS for INT230-6 alone (n=15) was 21.3 CI (4.7, NR) months. The maximum severity of INT230-6 treatment-related adverse events (TRAEs) in STS patients was 6.7% grade 1, 60% grade 2, and 33% grade 3 (no related grade 4 or 5 AEs). The most common TRAEs were pain, fatigue, and nausea. Methods: IT-03 is a 2:1 randomized trial comparing INT230-6 as monotherapy to an investigator’s choice of pazopanib, trabectedin, or eribulin, per label. A total of 333 patients in 2L/3L will be enrolled in the US, Canada, Europe, and Australia. INT230-6 dose is set by tumor size. INT230-6 is given IT Q2W for up to 5 doses to as many tumors >1 cm as is deemed safe. Maintenance is Q12 weeks for up to 22 months. Statistics: 90% power to detect a survival HR of 0.65 with 3 interim assessments at 20%, 40%, and 60% of participants events (deaths). The final analysis is at 80% of events. There is a two-sided total alpha = 0.05, allocated as follows: interim #1 = 0.0039; #2 = 0.0184; final = 0.043. Includes up to 60 sites: several sites are now recruiting. Inclusion criteria: Must be ≥ 18 yo, and provide written consent, Proven, unresectable, locally advanced, or metastatic STS; Must have received at least one line of therapy and progressed after anthracycline therapy. 1 tumor for injection of at least 2 cm. Adequate organ function in screening; lab values of: Neutrophils ≥ 1500/μL (≥ 1.5× 10 9 /L). PT, and INR ≤ 1.5× ULN, platelets ≥ 100,000/μL; hemoglobin ≥ 9 g/dL. Criteria must be met without erythropoietin dependency or packed red blood cell transfusion within last 2 weeks. Creatinine normal; or clearance > 50 mL/min by the C-G equation. ALT SGOT/ AST SGPT ≤ 2.5× ULN without, and ≤ 5× ULN with hepatic metastases. Bilirubin (BR) ≤ 1.5× ULN (except those with Gilbert’s syndrome, who must have total BR ≤ 3.0 mg/dL [< 52 µmol/L]). CPK ≤ 2.5× ULN. Clinical trial information: NCT06263231 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.002 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.002 | 0.003 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".